Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
JCR Terminates Temcell Development for Epidermolysis Bullosa
JCR Pharmaceuticals said on March 8 that it will call off the development of its human mesenchymal stem cell therapy Temcell for an additional indication of epidermolysis bullosa (EB) after dropping its submission in 2019. The company filed the therapy…
To read the full story
Related Article
- JCR Drops Temcell Submission for Epidermolysis Bullosa
September 20, 2019
- JCR Files Temcell for Epidermolysis Bullosa
March 25, 2019
- JCR Initiates Development of Temcell for Epidermolysis Bullosa
October 30, 2018
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
- Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…